APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angiogenesis Modulators

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Angiogenesis Modulators Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchAngiogenesis Modulators Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiogenesis Modulators Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Angiogenesis Modulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiogenesis Modulators Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiogenesis Modulators Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Angiogenesis Modulators market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Angiogenesis Modulators market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Angiogenesis Modulators market include Bayer Pharma AG (Germany), Bionomics Ltd. (Australia), CASI Pharmaceuticals, Inc. (USA), Celgene Corporation (USA), F.Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (USA), AstraZeneca plc (UK), Amgen, Inc. (USA) and GlaxoSmithKline plc (UK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiogenesis Modulators market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiogenesis Modulators and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiogenesis Modulators sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiogenesis Modulators market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiogenesis Modulators Segment by Company

Bayer Pharma AG (Germany)

Bionomics Ltd. (Australia)

CASI Pharmaceuticals, Inc. (USA)

Celgene Corporation (USA)

F.Hoffmann-La Roche AG (Switzerland)

Genentech, Inc. (USA)

AstraZeneca plc (UK)

Amgen, Inc. (USA)

GlaxoSmithKline plc (UK)

Eli Lilly and Company (USA)

Eisai (Japan)

Angiogenesis Modulators Segment by Type

Angiogenesis Stimulators

Angiogenin

Angiogenesis Inhibitors

Others

Angiogenesis Modulators Segment by Application

Breast Cancer

Prostate Cancer

Colorectal Cancer

Lung Cancer

Others

Angiogenesis Modulators Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Angiogenesis Modulators status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Angiogenesis Modulators market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Angiogenesis Modulators significant trends, drivers, influence factors in global and regions.

6. To analyze Angiogenesis Modulators competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Modulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Modulators and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Modulators.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiogenesis Modulators market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Angiogenesis Modulators industry.

Chapter 3: Detailed analysis of Angiogenesis Modulators manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Angiogenesis Modulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Angiogenesis Modulators in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Angiogenesis Modulators Industry Trends Table 2. Angiogenesis Modulators Industry Drivers Table 3. Angiogenesis Modulators Industry Opportunities and Challenges Table 4. Angiogenesis Modulators Industry Restraints Table 5. Global Angiogenesis Modulators Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Angiogenesis Modulators Revenue Share by Company (2021-2026) Table 7. Global Angiogenesis Modulators Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Angiogenesis Modulators Sales Volume Share by Company (2021-2026) Table 9. Global Angiogenesis Modulators Average Price (US$/ton) of Company (2021-2026) Table 10. Global Angiogenesis Modulators Company Ranking, (2024-2026) & (USD Million) Table 11. Global Angiogenesis Modulators Key Company Manufacturing Base & Headquarters Table 12. Global Angiogenesis Modulators Company, Product Type & Application Table 13. Global Angiogenesis Modulators Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiogenesis Modulators by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Angiogenesis Stimulators Table 18. Significant Companies of Angiogenin Table 19. Significant Companies of Angiogenesis Inhibitors Table 20. Significant Companies of Others Table 21. Global Angiogenesis Modulators Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 22. Global Angiogenesis Modulators Sales Volume by Type (2021-2026) & (k tons) Table 23. Global Angiogenesis Modulators Sales Volume by Type (2027-2032) & (k tons) Table 24. Global Angiogenesis Modulators Sales Volume Share by Type (2021-2026) Table 25. Global Angiogenesis Modulators Sales Volume Share by Type (2027-2032) Table 26. Global Angiogenesis Modulators Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Angiogenesis Modulators Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Angiogenesis Modulators Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Angiogenesis Modulators Sales Value Share by Type (2021-2026) Table 30. Global Angiogenesis Modulators Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Breast Cancer Table 32. Significant Companies of Prostate Cancer Table 33. Significant Companies of Colorectal Cancer Table 34. Significant Companies of Lung Cancer Table 35. Significant Companies of Others Table 36. Global Angiogenesis Modulators Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 37. Global Angiogenesis Modulators Sales Volume by Application (2021-2026) & (k tons) Table 38. Global Angiogenesis Modulators Sales Volume by Application (2027-2032) & (k tons) Table 39. Global Angiogenesis Modulators Sales Volume Share by Application (2021-2026) Table 40. Global Angiogenesis Modulators Sales Volume Share by Application (2027-2032) Table 41. Global Angiogenesis Modulators Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Angiogenesis Modulators Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Angiogenesis Modulators Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Angiogenesis Modulators Sales Value Share by Application (2021-2026) Table 45. Global Angiogenesis Modulators Sales Value Share by Application (2027-2032) Table 46. Global Angiogenesis Modulators Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 47. Global Angiogenesis Modulators Sales by Region (2021-2026) & (k tons) Table 48. Global Angiogenesis Modulators Sales Market Share by Region (2021-2026) Table 49. Global Angiogenesis Modulators Sales by Region (2027-2032) & (k tons) Table 50. Global Angiogenesis Modulators Sales Market Share by Region (2027-2032) Table 51. Global Angiogenesis Modulators Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Angiogenesis Modulators Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Angiogenesis Modulators Sales Value Share by Region (2021-2026) Table 54. Global Angiogenesis Modulators Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Angiogenesis Modulators Sales Value Share by Region (2027-2032) Table 56. Global Angiogenesis Modulators Market Average Price (US$/ton) by Region (2021-2026) Table 57. Global Angiogenesis Modulators Market Average Price (US$/ton) by Region (2027-2032) Table 58. Global Angiogenesis Modulators Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 59. Global Angiogenesis Modulators Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Angiogenesis Modulators Sales by Country (2021-2026) & (k tons) Table 61. Global Angiogenesis Modulators Sales Market Share by Country (2021-2026) Table 62. Global Angiogenesis Modulators Sales by Country (2027-2032) & (k tons) Table 63. Global Angiogenesis Modulators Sales Market Share by Country (2027-2032) Table 64. Global Angiogenesis Modulators Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Angiogenesis Modulators Sales Value Market Share by Country (2021-2026) Table 66. Global Angiogenesis Modulators Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Angiogenesis Modulators Sales Value Market Share by Country (2027-2032) Table 68. Bayer Pharma AG (Germany) Company Information Table 69. Bayer Pharma AG (Germany) Business Overview Table 70. Bayer Pharma AG (Germany) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 71. Bayer Pharma AG (Germany) Angiogenesis Modulators Product Portfolio Table 72. Bayer Pharma AG (Germany) Recent Development Table 73. Bionomics Ltd. (Australia) Company Information Table 74. Bionomics Ltd. (Australia) Business Overview Table 75. Bionomics Ltd. (Australia) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. Bionomics Ltd. (Australia) Angiogenesis Modulators Product Portfolio Table 77. Bionomics Ltd. (Australia) Recent Development Table 78. CASI Pharmaceuticals, Inc. (USA) Company Information Table 79. CASI Pharmaceuticals, Inc. (USA) Business Overview Table 80. CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 81. CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Product Portfolio Table 82. CASI Pharmaceuticals, Inc. (USA) Recent Development Table 83. Celgene Corporation (USA) Company Information Table 84. Celgene Corporation (USA) Business Overview Table 85. Celgene Corporation (USA) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 86. Celgene Corporation (USA) Angiogenesis Modulators Product Portfolio Table 87. Celgene Corporation (USA) Recent Development Table 88. F.Hoffmann-La Roche AG (Switzerland) Company Information Table 89. F.Hoffmann-La Roche AG (Switzerland) Business Overview Table 90. F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 91. F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Product Portfolio Table 92. F.Hoffmann-La Roche AG (Switzerland) Recent Development Table 93. Genentech, Inc. (USA) Company Information Table 94. Genentech, Inc. (USA) Business Overview Table 95. Genentech, Inc. (USA) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 96. Genentech, Inc. (USA) Angiogenesis Modulators Product Portfolio Table 97. Genentech, Inc. (USA) Recent Development Table 98. AstraZeneca plc (UK) Company Information Table 99. AstraZeneca plc (UK) Business Overview Table 100. AstraZeneca plc (UK) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 101. AstraZeneca plc (UK) Angiogenesis Modulators Product Portfolio Table 102. AstraZeneca plc (UK) Recent Development Table 103. Amgen, Inc. (USA) Company Information Table 104. Amgen, Inc. (USA) Business Overview Table 105. Amgen, Inc. (USA) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 106. Amgen, Inc. (USA) Angiogenesis Modulators Product Portfolio Table 107. Amgen, Inc. (USA) Recent Development Table 108. GlaxoSmithKline plc (UK) Company Information Table 109. GlaxoSmithKline plc (UK) Business Overview Table 110. GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 111. GlaxoSmithKline plc (UK) Angiogenesis Modulators Product Portfolio Table 112. GlaxoSmithKline plc (UK) Recent Development Table 113. Eli Lilly and Company (USA) Company Information Table 114. Eli Lilly and Company (USA) Business Overview Table 115. Eli Lilly and Company (USA) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 116. Eli Lilly and Company (USA) Angiogenesis Modulators Product Portfolio Table 117. Eli Lilly and Company (USA) Recent Development Table 118. Eisai (Japan) Company Information Table 119. Eisai (Japan) Business Overview Table 120. Eisai (Japan) Angiogenesis Modulators Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 121. Eisai (Japan) Angiogenesis Modulators Product Portfolio Table 122. Eisai (Japan) Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Angiogenesis Modulators Distributors List Table 126. Angiogenesis Modulators Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Angiogenesis Modulators Product Image Figure 2. Global Angiogenesis Modulators Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiogenesis Modulators Sales Value (2021-2032) & (US$ Million) Figure 4. Global Angiogenesis Modulators Sales (2021-2032) & (k tons) Figure 5. Global Angiogenesis Modulators Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Angiogenesis Modulators Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Angiogenesis Stimulators Image Figure 10. Angiogenin Image Figure 11. Angiogenesis Inhibitors Image Figure 12. Others Image Figure 13. Global Angiogenesis Modulators Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 14. Global Angiogenesis Modulators Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Angiogenesis Modulators Sales Volume Share by Type (2021-2032) Figure 16. Global Angiogenesis Modulators Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Angiogenesis Modulators Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Angiogenesis Modulators Sales Value Share by Type (2021-2032) Figure 19. Breast Cancer Image Figure 20. Prostate Cancer Image Figure 21. Colorectal Cancer Image Figure 22. Lung Cancer Image Figure 23. Others Image Figure 24. Global Angiogenesis Modulators Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 25. Global Angiogenesis Modulators Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Angiogenesis Modulators Sales Volume Share by Application (2021-2032) Figure 27. Global Angiogenesis Modulators Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Angiogenesis Modulators Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Angiogenesis Modulators Sales Value Share by Application (2021-2032) Figure 30. Global Angiogenesis Modulators Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 31. Global Angiogenesis Modulators Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Angiogenesis Modulators Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Angiogenesis Modulators Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Angiogenesis Modulators Sales Value (2021-2032) & (US$ Million) Figure 35. North America Angiogenesis Modulators Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Angiogenesis Modulators Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Angiogenesis Modulators Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Angiogenesis Modulators Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Angiogenesis Modulators Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Angiogenesis Modulators Sales Value (2021-2032) & (US$ Million) Figure 41. South America Angiogenesis Modulators Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Angiogenesis Modulators Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Angiogenesis Modulators Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Angiogenesis Modulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Angiogenesis Modulators Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Angiogenesis Modulators Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Angiogenesis Stimulators
  • Angiogenin
  • Angiogenesis Inhibitors
  • Others
Applications
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Others
Companies covered
  • Bayer Pharma AG (Germany)
  • Bionomics Ltd. (Australia)
  • CASI Pharmaceuticals, Inc. (USA)
  • Celgene Corporation (USA)
  • F.Hoffmann-La Roche AG (Switzerland)
  • Genentech, Inc. (USA)
  • AstraZeneca plc (UK)
  • Amgen, Inc. (USA)
  • GlaxoSmithKline plc (UK)
  • Eli Lilly and Company (USA)
  • Eisai (Japan)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Angiogenesis Modulators Sales Value (2021-2032)
  4. 1.2.2 Global Angiogenesis Modulators Sales Volume (2021-2032)
  5. 1.2.3 Global Angiogenesis Modulators Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Angiogenesis Modulators Market Dynamics
  1. 2.1 Angiogenesis Modulators Industry Trends
  2. 2.2 Angiogenesis Modulators Industry Drivers
  3. 2.3 Angiogenesis Modulators Industry Opportunities and Challenges
  4. 2.4 Angiogenesis Modulators Industry Restraints
3 Angiogenesis Modulators Market by Company
  1. 3.1 Global Angiogenesis Modulators Company Revenue Ranking in 2025
  2. 3.2 Global Angiogenesis Modulators Revenue by Company (2021-2026)
  3. 3.3 Global Angiogenesis Modulators Sales Volume by Company (2021-2026)
  4. 3.4 Global Angiogenesis Modulators Average Price by Company (2021-2026)
  5. 3.5 Global Angiogenesis Modulators Company Ranking (2024-2026)
  6. 3.6 Global Angiogenesis Modulators Company Manufacturing Base and Headquarters
  7. 3.7 Global Angiogenesis Modulators Company Product Type and Application
  8. 3.8 Global Angiogenesis Modulators Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Angiogenesis Modulators Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Angiogenesis Modulators Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Angiogenesis Modulators Market by Type
  1. 4.1 Angiogenesis Modulators Type Introduction
  2. 4.1.1 Angiogenesis Stimulators
  3. 4.1.2 Angiogenin
  4. 4.1.3 Angiogenesis Inhibitors
  5. 4.1.4 Others
  6. 4.2 Global Angiogenesis Modulators Sales Volume by Type
  7. 4.2.1 Global Angiogenesis Modulators Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Angiogenesis Modulators Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Angiogenesis Modulators Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Angiogenesis Modulators Sales Value by Type
  11. 4.3.1 Global Angiogenesis Modulators Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Angiogenesis Modulators Sales Value by Type (2021-2032)
  13. 4.3.3 Global Angiogenesis Modulators Sales Value Share by Type (2021-2032)
5 Angiogenesis Modulators Market by Application
  1. 5.1 Angiogenesis Modulators Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Others
  7. 5.2 Global Angiogenesis Modulators Sales Volume by Application
  8. 5.2.1 Global Angiogenesis Modulators Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Angiogenesis Modulators Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Angiogenesis Modulators Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Angiogenesis Modulators Sales Value by Application
  12. 5.3.1 Global Angiogenesis Modulators Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Angiogenesis Modulators Sales Value by Application (2021-2032)
  14. 5.3.3 Global Angiogenesis Modulators Sales Value Share by Application (2021-2032)
6 Angiogenesis Modulators Regional Sales and Value Analysis
  1. 6.1 Global Angiogenesis Modulators Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiogenesis Modulators Sales by Region (2021-2032)
  3. 6.2.1 Global Angiogenesis Modulators Sales by Region: 2021-2026
  4. 6.2.2 Global Angiogenesis Modulators Sales by Region (2027-2032)
  5. 6.3 Global Angiogenesis Modulators Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Angiogenesis Modulators Sales Value by Region (2021-2032)
  7. 6.4.1 Global Angiogenesis Modulators Sales Value by Region: 2021-2026
  8. 6.4.2 Global Angiogenesis Modulators Sales Value by Region (2027-2032)
  9. 6.5 Global Angiogenesis Modulators Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Angiogenesis Modulators Sales Value (2021-2032)
  12. 6.6.2 North America Angiogenesis Modulators Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Angiogenesis Modulators Sales Value (2021-2032)
  15. 6.7.2 Europe Angiogenesis Modulators Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Angiogenesis Modulators Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Angiogenesis Modulators Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Angiogenesis Modulators Sales Value (2021-2032)
  21. 6.9.2 South America Angiogenesis Modulators Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Angiogenesis Modulators Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Angiogenesis Modulators Sales Value Share by Country, 2025 VS 2032
7 Angiogenesis Modulators Country-level Sales and Value Analysis
  1. 7.1 Global Angiogenesis Modulators Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Angiogenesis Modulators Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Angiogenesis Modulators Sales by Country (2021-2032)
  4. 7.3.1 Global Angiogenesis Modulators Sales by Country (2021-2026)
  5. 7.3.2 Global Angiogenesis Modulators Sales by Country (2027-2032)
  6. 7.4 Global Angiogenesis Modulators Sales Value by Country (2021-2032)
  7. 7.4.1 Global Angiogenesis Modulators Sales Value by Country (2021-2026)
  8. 7.4.2 Global Angiogenesis Modulators Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Angiogenesis Modulators Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Angiogenesis Modulators Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Angiogenesis Modulators Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer Pharma AG (Germany)
  2. 8.1.1 Bayer Pharma AG (Germany) Company Information
  3. 8.1.2 Bayer Pharma AG (Germany) Business Overview
  4. 8.1.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Pharma AG (Germany) Angiogenesis Modulators Product Portfolio
  6. 8.1.5 Bayer Pharma AG (Germany) Recent Developments
  7. 8.2 Bionomics Ltd. (Australia)
  8. 8.2.1 Bionomics Ltd. (Australia) Company Information
  9. 8.2.2 Bionomics Ltd. (Australia) Business Overview
  10. 8.2.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bionomics Ltd. (Australia) Angiogenesis Modulators Product Portfolio
  12. 8.2.5 Bionomics Ltd. (Australia) Recent Developments
  13. 8.3 CASI Pharmaceuticals, Inc. (USA)
  14. 8.3.1 CASI Pharmaceuticals, Inc. (USA) Company Information
  15. 8.3.2 CASI Pharmaceuticals, Inc. (USA) Business Overview
  16. 8.3.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Product Portfolio
  18. 8.3.5 CASI Pharmaceuticals, Inc. (USA) Recent Developments
  19. 8.4 Celgene Corporation (USA)
  20. 8.4.1 Celgene Corporation (USA) Company Information
  21. 8.4.2 Celgene Corporation (USA) Business Overview
  22. 8.4.3 Celgene Corporation (USA) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Celgene Corporation (USA) Angiogenesis Modulators Product Portfolio
  24. 8.4.5 Celgene Corporation (USA) Recent Developments
  25. 8.5 F.Hoffmann-La Roche AG (Switzerland)
  26. 8.5.1 F.Hoffmann-La Roche AG (Switzerland) Company Information
  27. 8.5.2 F.Hoffmann-La Roche AG (Switzerland) Business Overview
  28. 8.5.3 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Product Portfolio
  30. 8.5.5 F.Hoffmann-La Roche AG (Switzerland) Recent Developments
  31. 8.6 Genentech, Inc. (USA)
  32. 8.6.1 Genentech, Inc. (USA) Company Information
  33. 8.6.2 Genentech, Inc. (USA) Business Overview
  34. 8.6.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Genentech, Inc. (USA) Angiogenesis Modulators Product Portfolio
  36. 8.6.5 Genentech, Inc. (USA) Recent Developments
  37. 8.7 AstraZeneca plc (UK)
  38. 8.7.1 AstraZeneca plc (UK) Company Information
  39. 8.7.2 AstraZeneca plc (UK) Business Overview
  40. 8.7.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca plc (UK) Angiogenesis Modulators Product Portfolio
  42. 8.7.5 AstraZeneca plc (UK) Recent Developments
  43. 8.8 Amgen, Inc. (USA)
  44. 8.8.1 Amgen, Inc. (USA) Company Information
  45. 8.8.2 Amgen, Inc. (USA) Business Overview
  46. 8.8.3 Amgen, Inc. (USA) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Amgen, Inc. (USA) Angiogenesis Modulators Product Portfolio
  48. 8.8.5 Amgen, Inc. (USA) Recent Developments
  49. 8.9 GlaxoSmithKline plc (UK)
  50. 8.9.1 GlaxoSmithKline plc (UK) Company Information
  51. 8.9.2 GlaxoSmithKline plc (UK) Business Overview
  52. 8.9.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline plc (UK) Angiogenesis Modulators Product Portfolio
  54. 8.9.5 GlaxoSmithKline plc (UK) Recent Developments
  55. 8.10 Eli Lilly and Company (USA)
  56. 8.10.1 Eli Lilly and Company (USA) Company Information
  57. 8.10.2 Eli Lilly and Company (USA) Business Overview
  58. 8.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly and Company (USA) Angiogenesis Modulators Product Portfolio
  60. 8.10.5 Eli Lilly and Company (USA) Recent Developments
  61. 8.11 Eisai (Japan)
  62. 8.11.1 Eisai (Japan) Company Information
  63. 8.11.2 Eisai (Japan) Business Overview
  64. 8.11.3 Eisai (Japan) Angiogenesis Modulators Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Eisai (Japan) Angiogenesis Modulators Product Portfolio
  66. 8.11.5 Eisai (Japan) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiogenesis Modulators Value Chain Analysis
  2. 9.1.1 Angiogenesis Modulators Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiogenesis Modulators Sales Mode & Process
  6. 9.2 Angiogenesis Modulators Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiogenesis Modulators Distributors
  9. 9.2.3 Angiogenesis Modulators Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst